Cargando…
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of patients who have an observed tumour shrinkage above a predefined level...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724692/ https://www.ncbi.nlm.nih.gov/pubmed/28850689 http://dx.doi.org/10.1002/sim.7453 |